Amicus Therapeutics Inc. (NASDAQ:FOLD) went down by -1.86% from its latest closing price compared to the recent 1-year high of $17.67. The company’s stock price has collected 7.19% of gains in the last five trading sessions. Press Release reported on 10/12/20 that Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society
Is It Worth Investing in Amicus Therapeutics Inc. (NASDAQ :FOLD) Right Now?
Plus, the 36-month beta value for FOLD is at 1.61. Opinions of the stock are interesting as 9 analysts out of 11 who provided ratings for Amicus Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $20.09, which is $2.65 above the current price. FOLD currently public float of 231.75M and currently shorts hold a 12.87% ratio of that float. Today, the average trading volume of FOLD was 2.02M shares.
FOLD’s Market Performance
FOLD stocks went up by 7.19% for the week, with a monthly jump of 15.41% and a quarterly performance of 14.08%, while its annual performance rate touched 107.38%. The volatility ratio for the week stands at 5.49% while the volatility levels for the past 30 days are set at 4.78% for Amicus Therapeutics Inc.. The simple moving average for the period of the last 20 days is 14.63% for FOLD stocks with a simple moving average of 36.77% for the last 200 days.
Analysts’ Opinion of FOLD
Many brokerage firms have already submitted their reports for FOLD stocks, with BTIG Research repeating the rating for FOLD by listing it as a “Buy.” The predicted price for FOLD in the upcoming period, according to BTIG Research is $19 based on the research report published on June 17th of the current year 2020.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see FOLD reach a price target of $20, previously predicting the price at $19. The rating they have provided for FOLD stocks is “Overweight” according to the report published on February 04th, 2020.
H.C. Wainwright gave a rating of “Buy” to FOLD, setting the target price at $20 in the report published on November 12th of the previous year.
FOLD Trading at 16.56% from the 50-Day Moving Average
After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.64% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 5.49%, as shares surge +25.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.34% upper at present.
During the last 5 trading sessions, FOLD rose by +7.19%, which changed the moving average for the period of 200-days by +83.55% in comparison to the 20-day moving average, which settled at $14.87. In addition, Amicus Therapeutics Inc. saw 73.00% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at FOLD starting from Do Hung, who sale 193,700 shares at the price of $15.03 back on Oct 09. After this action, Do Hung now owns 520,807 shares of Amicus Therapeutics Inc., valued at $2,911,272 using the latest closing price.
WHITMAN BURKE W, the Director of Amicus Therapeutics Inc., purchase 1,500 shares at $14.28 during a trade that took place back on Oct 01, which means that WHITMAN BURKE W is holding 35,467 shares at $21,413 based on the most recent closing price.
Stock Fundamentals for FOLD
Current profitability levels for the company are sitting at:
- -165.03 for the present operating margin
- +85.33 for the gross margin
The net margin for Amicus Therapeutics Inc. stands at -195.56. The total capital return value is set at -44.51, while invested capital returns managed to touch -53.03. Equity return is now at value -65.50, with -36.90 for asset returns.
Based on Amicus Therapeutics Inc. (FOLD), the company’s capital structure generated 44.13 points at debt to equity in total, while total debt to capital is 30.62. Total debt to assets is 24.73, with long-term debt to equity ratio resting at 42.62. Finally, the long-term debt to capital ratio is 29.57.
When we switch over and look at the enterrpise to sales, we see a ratio of 11.52, with the company’s debt to enterprise value settled at 0.10. The receivables turnover for the company is 6.60 and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.04.